Related Experiment Video

Updated: Sep 28, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
11:36

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms

Published on: May 29, 2020

Hepatitis B immunization in low birthweight infants: do they need an additional dose?

N K Arora1, S Ganguly, S N Agadi

  • 1Department of Pediatrics, All India Institute of Medical Sciences, New Delhi. nkmanan@hotmail.com

Acta Paediatrica (Oslo, Norway : 1992)
|November 5, 2002
PubMed

Insights

Preterm infants benefit from an additional hepatitis B vaccine dose for protective anti-HB levels, while term intrauterine growth-retarded infants should follow standard schedules. This strategy aims to prevent vertical transmission and enhance immune response in preterm infants.

Area of Science:

  • Immunology
  • Pediatrics
  • Vaccinology

Background:

  • Hepatitis B virus (HBV) infection poses a significant risk, especially in endemic areas.
  • Assessing the immune response to HBV vaccination in preterm (PT) and term intrauterine growth-retarded (T-IUGR) infants is crucial for effective prevention strategies.
  • Understanding the impact of gestational age and birth weight on vaccine efficacy is essential for optimizing infant immunization schedules.

Purpose of the Study:

  • To evaluate the influence of gestation and birth weight on protective anti-hepatitis B (anti-HB) antibody levels after three doses of HBV vaccine.
  • To determine the necessity of a fourth HBV vaccine dose for low birthweight infants.
  • To compare the immune response between PT and T-IUGR infants.

Main Methods:

  • A study involving 82 PT and 60 T-IUGR infants who received the Enivac HB vaccine at birth and at 6, 10, and 14 weeks of life.
  • Measurement of protective anti-HB levels (>10 mIU/ml) after the third and fourth vaccine doses.
  • Analysis of the association between gestational age, birth weight, maternal anti-HB antibodies, and vaccine response.

Main Results:

  • Protective anti-HB levels were achieved in 86.6% of PT infants and 96.7% of T-IUGR infants after three doses.
  • Increased gestation was associated with a higher likelihood of a protective response (odds ratio 1.25 per week increase).
  • A fourth vaccine dose significantly increased protective antibody levels in PT infants, particularly those without maternal antibodies, but offered no benefit to T-IUGR infants.

Conclusions:

  • Preterm infants, regardless of birth weight, may benefit from an additional HBV vaccine dose in a schedule starting at birth to prevent vertical transmission and match term infant immune responses.
  • Term intrauterine growth-retarded infants should adhere to the standard vaccination schedule for normal term infants.
  • Further research with different vaccine formulations and longer follow-up is needed to widely implement this strategy.
Abstract

More Related Videos

Multicellular Human Alveolar Model Composed of Epithelial Cells and Primary Immune Cells for Hazard Assessment09:27

Multicellular Human Alveolar Model Composed of Epithelial Cells and Primary Immune Cells for Hazard Assessment

Published on: May 6, 2020

Related Concept Videos

Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
Vaccinations01:51

Vaccinations

Overview
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...